A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants
Status:
Not yet recruiting
Trial end date:
2027-07-20
Target enrollment:
Participant gender:
Summary
This study is to determine the safety and preliminary efficacy of sabatolimab in combination
with magrolimab and azacitidine in adult participants with 1L unfit Acute Myeloid Leukemia
(AML) or with 1L higher risk Myelodysplastic Syndromes (MDS), and sabatolimab in combination
with magrolimab in participants with relapsed or refractory (R/R) AML.